Espansione Group Launches Second Wave of Global Clinical Trial for Dry AMD

Espansione Group announced today the second wave of its major research effort aimed at contributing to the prevention and management of dry AMD.   

Having announced the European study LightWave I at ESCRS 2022 in Milan, Espansione Group is today announcing a second large-scale, global multi-center clinical trial focused on non-neovascular (dry) Age-Related Macular Degeneration (AMD) through its patented technology Light Modulation® Low-level Light Therapy (LM® LLLT), a medical-grade photobiomodulation (PBM) technology already benefitting with strong support from the scientific community with dozens of papers and articles published to date. 

LightWave II is being announced today with the aim of strengthening the already existing body of research around PBM in AMD management, fill the knowledge gaps of LightWave I, and move beyond Europe with an additional focus on the American and Asia-Pacific Continents.  

Clinical trials conducted to date focusing on PBM in the field of retinal diseases have demonstrated better anatomical and functional outcomes for patients treated with LLLT vs. control groups. A large array of positive clinical findings, coupled with the well-known mitochondrial-based mode of action of LM® LLLT highly suggest that LLLT treatment could have a therapeutic role in dry AMD.

For practitioners, research centers and universities interested in staying in touch and learning more about LightWave II, its protocol and any future development,  reach Espansione Group at https://espansionegroup.it/lightwave-ii/